AstraZeneca moved to cancel a Phase 3 lung cancer trial of volrustomig after an interim look indicated the therapy was unlikely to achieve survival endpoints versus an existing comparator. The decision adds to a recent sequence of pipeline pressure as AstraZeneca tries to sustain late-stage momentum across its oncology franchises. The company said an independent data monitoring committee flagged that combined volrustomig plus chemotherapy would likely miss planned efficacy goals, prompting the end-of-study action. AstraZeneca now needs to reassess what role—if any—volrustomig could play in future combinations. For investors, the halt further narrows the company’s lung cancer options while highlighting how hard survival endpoints remain to clear for bispecific-like strategies entering late-stage oncology.